Items where authors include "Campochiaro, C."

Article

Campochiaro, C., Suliman, Y.A., Giuggioli, D. et al. (21 more authors) (2025) Recommendations for the local management of digital ulcers in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) 'Ad hoc committee'. Journal of Scleroderma and Related Disorders. ISSN 2397-1983

De Lorenzis, E., Natalello, G., Pellegrino, G. et al. (29 more authors) (2024) Long-term retention rate, adverse event temporal patterns and rescue treatment strategies of mycophenolate mofetil in systemic sclerosis: insights from real-life. Rheumatology. keae532. ISSN 1462-0324

Avanoglu-Guler, A. orcid.org/0000-0001-9866-9797, Campochiaro, C., De Luca, G. et al. (6 more authors) (2024) Calcinosis in systemic sclerosis: An update on pathogenesis, related complications, and management: A heavy burden still waiting to be lifted off patients’ hands. Seminars in Arthritis and Rheumatism, 66. 152431. ISSN 0049-0172

Deibel, E. orcid.org/0000-0003-4652-9826, Carreira, P.E., Vonk, M. orcid.org/0000-0002-2266-9907 et al. (61 more authors) (2024) Does the Impact of COVID-19 on Patients With Systemic Sclerosis Change Over Time? Arthritis Care & Research, 76 (1). pp. 88-97. ISSN 2151-464X

Lescoat, A., Bellando-Randone, S., Campochiaro, C. et al. (9 more authors) (2023) Beyond very early systemic sclerosis: deciphering pre‑scleroderma and its trajectories to open new avenues for preventive medicine. The Lancet Rheumatology, 5 (11). e683-e694. ISSN 2665-9913

Garaiman, A., Steigmiller, K., Gebhard, C. et al. (171 more authors) (2023) Use of platelet inhibitors for digital ulcers related to systemic sclerosis: EUSTAR study on derivation and validation of the DU-VASC model. Rheumatology, 62 (SI). SI91-SI100. ISSN 1462-0324

Campochiaro, C. orcid.org/0000-0001-6806-3794, Hoffmann-Vold, A.-M. orcid.org/0000-0001-6467-7422, Avouac, J. et al. (90 more authors) (2022) Sex influence on outcomes of patients with systemic sclerosis–associated interstitial lung disease: a EUSTAR database analysis. Rheumatology, 62 (7). pp. 2483-2491. ISSN 1462-0324

Lazzaroni, M-G., Marasco, E., Campochiaro, C. et al. (30 more authors) (2021) The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. Rheumatology, 60 (11). pp. 5028-5041. ISSN 1462-0324

Conference or Workshop Item

Campochiaro, C., Mongin, D., Courvoisier, D.S. et al. (16 more authors) (2025) OP0082 Evidence-based detection of progression of systemic sclerosis-interstitial lung disease patients: the EUSTAR-PPF study (CP number 148). In: EULAR 2025: European Congress of Rheumatology, 11-14 Jun 2025, Barcelona, Spain.

Verardi, L., De Lorenzis, E., Pellegrino, G. et al. (19 more authors) (2023) POS1324 mycophenolate mofetil use in clinical practice in a multicentric cohort of scleroderma patients: persistence on therapy and long-term adverse events. In: EULAR 2023 European Congress of Rheumatology, 31 May - 03 Jun 2023, Milan, Italy.

Proceedings Paper

Benfaremo, D., Campochiaro, C., Kumánovics, G. et al. (16 more authors) (2025) OP0085 Outcomes of upfront combination vs monotherapy with rituximab or mycophenolate mofetil for systemic sclerosis interstitial lung disease (SSc-ILD): results from an EUSTAR cohort study. In: Annals of the Rheumatic Diseases. EULAR 2025: European Congress of Rheumatology, 11-14 Jun 2025, Barcelona, Spain. Elsevier , p. 75.

D'Alessandro, R., Rodolfi, S., Calot, A. et al. (20 more authors) (2025) ABS0554 FEATURES OF ANTI-FIBRILLARIN POSITIVE SYSTEMIC SCLEROSIS PATIENTS AND ETHNIC DIFFERENCES: A EUROPEAN MULTICENTRIC COHORT. In: Annals of the Rheumatic Diseases. EULAR 2025: European Congress of Rheumatology, 11-14 Jun 2025, Barcelona, Spain. Elsevier , pp. 2294-2295.

Campochiaro, C., Mongin, D., Courvoisier, D.S. et al. (16 more authors) (2025) OP0082 Evidence-based detection of progression of systemic sclerosis-interstitial lung disease patients: the EUSTAR-PPF study (CP number 148). In: Annals of the Rheumatic Diseases. EULAR 2025: European Congress of Rheumatology, 11-14 Jun 2025, Barcelona, Spain. Elsevier , pp. 72-73.

Benfaremo, D., Campochiaro, C., Kumanovics, G. et al. (16 more authors) (2025) OP0085 Outcomes of upfront combination vs monotherapy with rituximab or mycophenolate mofetil for systemic sclerosis interstitial lung disease (SSc-ILD): results from an EUSTAR cohort study. In: Annals of the Rheumatic Diseases. EULAR 2025: European Congress of Rheumatology, 11-14 Jun 2025, Barcelona, Spain. , p. 75.

Colic, J., Campochiaro, C., Del Papa, N. et al. (17 more authors) (2025) OP0216 DISEASE CHARACTERISTICS OF ANTI-CENTROMERE POSITIVE SYSTEMIC SCLEROSIS PATIENTS AND RISK FACTORS FOR ORGAN INVOLVEMENT: DATA FROM THE EUSTAR COHORT. In: Annals of the Rheumatic Diseases. EULAR 2025: European Congress of Rheumatology, 11-14 Jun 2025, Barcelona, Spain. Elsevier , pp. 179-180.

Moschetti, L., Rovaris, S., Bonomi, F. et al. (35 more authors) (2025) OP0217 THE CLINICAL PHENOTYPE OF ANTI-Th/To+ PATIENTS IN SYSTEMIC SCLEROSIS: A CASE-CONTROL STUDY WITHIN THE EUROPEAN SCLERODERMA TRIALS AND RESEARCH (EUSTAR) COHORT. In: Annals of the Rheumatic Diseases. EULAR 2025: European Congress of Rheumatology, 11-14 Jun 2025, Barcelona, Spain. BMJ Publishing Group , pp. 181-182.

Guler, A.A., Hughes, M., De Luca, G. et al. (17 more authors) (2025) OP0219 CLINICAL CHARACTERISTICS AND RISK FACTORS FOR CALCINOSIS CUTIS IN SYSTEMIC SCLEROSIS: INSIGHTS FROM THE EUROPEAN SCLERODERMA TRIAL AND RESEARCH GROUP (EUSTAR) DATABASE. In: Annals of the Rheumatic Diseases. EULAR 2025: European Congress of Rheumatology, 11-14 Jun 2025, Barcelona, Spain. BMJ Publishing Group , pp. 183-184.

Moschetti, L., Pedretti, E., Bonomi, F. et al. (27 more authors) (2024) The Clinical Phenotype of Anti-Th/To plus Patients in Systemic Sclerosis: A Case-control Study Within the European Scleroderma Trials and Research (EUSTAR) Cohort. In: Arthritis & Rheumatology. ACR Convergence 2024, 14-19 Nov 2024, Washington D.C., USA. Wiley , pp. 4955-4958.